Increased frequency of Myeloid-derived suppressor cells during active tuberculosis and after recent Mycobacterium tuberculosis infection suppresses T-cell function

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 6, 2013, Pages 724-732

  Du Plessis, Nelita ^a   Loebenberg, Laurianne ^a   Kriel, Magdalena ^a   Von Groote Bidlingmaier, Florian ^a   Ribechini, Eliana ^b   Loxton, Andre G ^a   Van Helden, Paul D ^a   Lutz, Manfred B ^b   Walzl, Gerhard ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Immunosuppression; Mycobacterium tuberculosis; Myeloid derived suppressor cells

Indexed keywords

CD11B ANTIGEN; CD33 ANTIGEN; CELL SURFACE MARKER; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUBERCULOSTATIC AGENT;

ARTICLE; BLOOD; BONE MARROW CELL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; COCULTURE; CONTROLLED STUDY; CYTOKINE RESPONSE; ENVIRONMENTAL EXPOSURE; FLOW CYTOMETRY; GRANULOCYTE; HOUSEHOLD; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER; LYMPHOCYTE FUNCTION; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; PLEURA TUMOR; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUBERCULIN TEST; TUBERCULOSIS;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; LUNG NEOPLASMS; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM TUBERCULOSIS; MYELOID CELLS; T-LYMPHOCYTES; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84884623869     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201302-0249OC     Document Type: Article

References (73)

1. Salgame P. Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection. Curr Opin Immunol 2005;17:374-380.
2. Scriba TJ, Kalsdorf B, Abrahams D-A, Isaacs F, Hofmeister J, Black G, Hassan HY, Wilkinson RJ, Walzl G, Gelderbloem SJ, et al. Distinct, specific IL-17-and IL-22-producing CD41 T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008;180:1962-1970.
3. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000;30:3689-3698.
4. Canaday DH, Wilkinson RJ, Li Q, Harding CV, Silver RF, Boom WH. CD4 (1) and CD8 (1) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism. J Immunol 2001;167:2734-2742.
5. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009;27:393-422.
6. Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 2012;10:407-416.
7. Kahnert A, Höpken UE, Stein M, Bandermann S, Lipp M, Kaufmann S H E. Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. J Infect Dis 2007;195:46-54.
8. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford T K A, Bucks C, Kane CM, Fallon PG, Pannell R, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010;464:1367-1370.
9. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
10. He X-Y, Xiao L, Chen H-B, Hao J, Li J, Wang Y-J, He K, Gao Y, Shi BY. T regulatory cells and Th1/Th2 cytokines in peripheral blood from tuberculosis patients. Eur J Clin Microbiol Infect Dis 2010;29:643-650.
11. Rook G A W. Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med 2007;7:327-337.
12. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-174.
13. Solito S, Bronte V, Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol 2011;90:31-36.
14. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kübler H, Yancey D, Dahm P, Vieweg J. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008;14:8270-8278.
15. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69:1553-1560.
16. Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fioravanti S, Manns MP, Greten TF, Korangy F. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology 2012;136:176-183.
17. Liu C-Y, Wang Y-M, Wang C-L, Feng P-H, Ko H-W, Liu Y-H, Wu YC, Chu Y, Chung FT, Kuo CH, et al. Population alterations of L-arginaseand inducible nitric oxide synthase-expressed CD11b1/CD14-/CD151/CD331 myeloid-derived suppressor cells and CD81 T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136:35-45.
18. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, et al. IL4Ralpha1 myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009;182:6562-6568.
19. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD141HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010;70:4335-4345.
20. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokineinduced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185:2273-2284.
21. Ribechini E, Greifenberg V, Sandwick S, Lutz MB. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol (Berl) 2010;199:273-281.
22. Brudecki L, Ferguson DA, McCall CE, El Gazzar M. Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect Immun 2012;80:2026-2034.
23. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD81 T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004;172:989-999.
24. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003;24:302-306.
25. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010;70:68-77.
26. Huang B, Pan P-Y, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. Gr-11CD1151 immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66:1123-1131.
27. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-b 1. J Immunol 2009;182:240-249.
28. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Chaudhury AR, La Perle KM, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 2011;71:5101-5110.
29. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD41 and CD81 T cells. J Immunol 2009;183:937-944.
30. Haile LA, von Wasielewski R, Gamrekelashvili J, Krüger C, Bachmann O, Westendorf AM, et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008;135:871-881.
31. Yin B, Ma G, Yen C-Y, Zhou Z, Wang GX, Divino CM, Casares S, Chen SH, Yang WC, Pan PY. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol 2010;185:5828-5834.
32. Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, Kuchroo VK, Khoury SJ. CD11b1Ly-6C (hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 2007;179:5228-5237.
33. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61:4756-4760.
34. Görgün GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013;121:2975-2987.
35. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008;118:3367-3377.
36. Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010;2010:201026.
37. Qin A, Cai W, Pan T, Wu K, Yang Q, Wang N, Liu Y, Yan D, Hu F, Guo P, et al. Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J Virol 2013;87:1477-1490.
38. Vollbrecht T, Stirner R, Tufman A, Roider J, Huber RM, Bogner JR, Lechner A, Bourquin C, Draenert R. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS 2012;26:F31-F37.
39. Gama L, Shirk EN, Russell JN, Carvalho KI, Li M, Queen SE, Kalil J, Zink MC, Clements JE, Kallas EG. Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection. J Leukoc Biol 2012;91:803-816.
40. De Santo C, Salio M, Masri SH, Lee LY-H, Dong T, Speak AO, Porubsky S, Booth S, Veerapen N, Besra GS, et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloidderived suppressor cells in mice and humans. J Clin Invest 2008;118:4036-4048.
41. Mencacci A, Montagnoli C, Bacci A, Cenci E, Pitzurra L, Spreca A, Kopf M, Sharpe AH, Romani L. CD801Gr-11 myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol 2002;169:3180-3190.
42. Martino A, Badell E, Abadie V, Balloy V, Chignard M, Mistou M-Y, Combadière B, Combadière C, Winter N. Mycobacterium bovis bacillus Calmette-Guérin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1R-dependent nitric oxide production. J Immunol 2010;184:2038-2047.
43. Wang Z, Jiang J, Li Z, Zhang J, Wang H, Qin Z. A myeloid cell population induced by Freund adjuvant suppresses T-cell-mediated antitumor immunity. J Immunother 2010;33:167-177.
44. Loebenberg L. Environmental influences on innate and adaptive immune responses against Mycobacterium tuberculosis [doctoral dissertation, Biomedical Sciences, University of Stellenbosch, 2011; accessed 2012]. Available from: http://scholar.sun. ac.za/handle/10019.1/6901
45. Baumgarth N, Roederer M. Apractical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods 2000;243:77-97.
46. Bøyum A. Separation of blood leucocytes, granulocytes and lymphocytes. Tissue Antigens 1974;4:269-274.
47. Zhang C, Lei G-S, Shao S, Jung H-W, Durant PJ, Lee C-H. Accumulation of myeloid-derived suppressor cells in the lungs during pneumocystis pneumonia. Infect Immun 2012;80:3634-3641.
48. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 2006;173:803-810.
49. Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, Suttmann H, Schenck M, Welling J, Zabel P, et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 2011;89:311-317.
50. Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009;182:3801-3808.
51. Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J Infect Dis 1993;167:1481-1497.
52. Hougardy J-M, Place S, Hildebrand M, Drowart A, Debrie A-S, Locht C, Mascart F. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med 2007;176:409-416.
53. Lee J-M, Seo J-H, Kim Y-J, Kim Y-S, Ko H-J, Kang C-Y. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int J Cancer 2012;131:741-751.
54. Dilioglou S, Cruse JM, Lewis RE. Function of CD80 and CD86 on monocyte-and stem cell-derived dendritic cells. Exp Mol Pathol 2003;75:217-227.
55. Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012;12:581-591.
56. Surcel HM, Troye-Blomberg M, Paulie S, Andersson G, Moreno C, Pasvol G, Ivanyi J. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 1994;81:171-176.
57. Galkina E, Tanousis K, Preece G, Tolaini M, Kioussis D, Florey O, Haskard DO, Tedder TF, Ager A. L-selectin shedding does not regulate constitutive T cell trafficking but controls the migration pathways of antigen-activated T lymphocytes. J Exp Med 2003;198:1323-1335.
58. Tang ML, Steeber DA, Zhang XQ, Tedder TF. Intrinsic differences in L-selectin expression levels affect T and B lymphocyte subset-specific recirculation pathways. J Immunol 1998;160:5113-5121.
59. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-712.
60. Chen X, Zhang M, Liao M, Graner MW, Wu C, Yang Q, Liu H, Zhou B. Reduced Th17 response in patients with tuberculosis correlates with IL-6R expression on CD41 T Cells. Am J Respir Crit Care Med 2010;181:734-742.
61. Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007;11:828-837.
62. Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, Dascher CC, Berezovskaya A, Rousset D, Reynes JM, Goldfeld AE. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000;105:1317-1325.
63. Delgado JC, Tsai EY, Thim S, Baena A, Boussiotis VA, Reynes J-M, Sath S, Grosjean P, Yunis EJ, Goldfeld AE. Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia. Proc Natl Acad Sci USA 2002;99:7576-7581.
64. Chen CY, Huang D, Wang RC, Shen L, Zeng G, Yao S, Shen Y, Halliday L, Fortman J, McAllister M, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 2009;5:e1000392.
65. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992;89:12013-12017.
66. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4 (1) CD25 (1) Foxp3 (1) T cells. Gastroenterology 2008;135:234-243.
67. Kursar M, Koch M, Mittrücker H-W, Nouailles G, Bonhagen K, Kamradt T, Kaufmann SH. Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J Immunol 2007;178:2661-2665.
68. Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O'Shea JJ, Shevach EM. CD41 FoxP31 regulatory T cells confer infectious tolerance in a TGF-b-dependent manner. J Exp Med 2008;205:1975-1981.
69. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005;6:353-360.
70. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 2010;207:1409-1420.
71. Pan P-Y, Wang GX, Yin B, Ozao J, Ku T, Divino CM, Chen SH. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stemcell factor function. Blood 2008;111:219-228.
72. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007;67:10019-10026.
73. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;58:49-59.